Activities

-. Task Force on “Standardization of (Primary) Clinical Outcomes for Clinical Trials in AIT

TF-Coordinators: Oliver Pfaar and Sabina Rak

Start-date: 2011, current status: ongoing

Rationale: Generally accepted and authoritative national and international guidelines are still lacking with respect to the assessment of the therapeutic effects of AIT by using clearly-defined symptom- and medication-scores. Therefore, the aim of the task-force will be to propose a position statement clearly defining how symptoms and medications should be assessed, analyzed and adequately weighted in prospective clinical trials on both SLIT and SCIT. Current status: EAACI-Position Paper in progress

-. Project "Semantics in SIT and MedDRA terminology for adverse reactions due to SIT" Coordinator: Pascal Demoly and Moises Calderon

Start date: 2011

Finish date: 2012

Rationale: Current semantic use to characterize allergen immunotherapy and terminology for adverse reactions is heterogeneous depending on the countries and/or the scientific societies.

Main objective:
To create a common language for all audiences regarding immunotherapy and identify semantic keys to reinforce the impact of communication on allergy immunotherapy. To create a harmonised MedDRA based terminology for the report of adverse reactions after SIT in a real life setting.

-. Task force on “Contraindications for AIT”

Coordinator:
Constantinos Pitsios

Start date: 2011

Finish date: 2013

Rationale: Despite the large number of papers published on SCIT and SLIT, there is still no common agreement on the “contra-indications” for SIT.

Main objective: To collect and compare clinical data on the effect of Allergen Immunotherapy on conditions and diseases that are currently considered as contraindications.
A systematic literature search has been performed to re-assess AIT contraindications and adapt them to the current situation of different diseases, co-morbidities and certain drugs. Current status: A Consensus Meeting has taken place on May 2013 and the Task Force Report - Position paper is in progress. An international survey (CONSIT) regarding the opinion of allergologists on AIT's contraindications has been performed and is soon going to be published.

Last updated 12 February 2015
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel